Crizotinib, a potent and specific small molecule inhibitor of both ALK and c-MET tyrosine kinases [8-10], was approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC) patients with ALK gene rearrangement (ALK+). The gene discussed is MET; the disease is non-small cell lung carcinoma.